Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vincera Pharma Announces Exclusive License Agreement with Bayer for Oncology Portfolio
Details : Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer...
Brand Name : VIP152
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 08, 2020
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?